'Big pharma' seeks a new global business model
You must be signed in to read this analysis
In this article
- Blockbuster business model
- Unbalanced revenue portfolios
- Vulnerable cash cows
- Ticking clock
- Dissipating market share
- Recalibration
- New sectors or divestment
- Smaller partners
- Boosting share prices
- New model?
What is this?
This article is from the Oxford Analytica Daily Brief, which analyses geopolitical, economic, social, business and industrial developments on a global and regional basis, providing clients with timely, authoritative analysis every business day of the year. Find out more about the Oxford Analytica Daily Brief, or request a trial.
_350.jpg "Various medicine pills. (REUTERS/Srdjan Zivulovic)")